Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Bispecific antibodies (bsAbs), engage and redirect T cells represent a significant percentage of programs in development is approved in the US for acute lymphoblastic leukemia.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
March 23, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable